Acute Kidney Injury after Administering Dapagliflozin to a Diabetic Patient with Acute Cerebral Infarction
10.3904/kjm.2020.95.6.404
- Author:
Changhyun PARK
1
;
Eun Kyoung LEE
;
So Mi KIM
;
Jong Tae CHO
;
Do Hyun LEE
;
Ji-eun LEE
;
Ji Hyun JEON
Author Information
1. Division of Nephrology, Department of Internal Medicine, Dankook University Hospital, Dankook University College of Medicine, Cheonan, Korea
- Publication Type:3
- From:Korean Journal of Medicine
2020;95(6):404-408
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Dapagliflozin is a recently developed oral anti-diabetic drug and SGLT2 inhibitor with well-known cardioprotective and renoprotective effects. Although a reduction of the glomerular filtration rate is induced by volume depletion and tubule-glomerular feedback during the early period after administering a SGLT2 inhibitor, the renal prognosis improves more with a decrease of proteinuria. However, the risk of acute kidney injury increases in heart failure and hypovolemia patients, and in those taking certain drugs, such as non-steroidal anti-inflammatory drugs, angiotensin-converting enzyme inhibitor/angiotensin II receptor blockers, or diuretics. We report acute kidney injury after dapagliflozin administration in a diabetic patient with acute cerebral infarction accompanied by right hemiplegia, motor aphasia, and dysphagia.
